08:46 AM EST - Oncolytics Biotech Inc : Today issued a corporate update to provide investors with a deeper understanding of recent data and what is expected for 2025. Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval. Key milestones in gastrointestinal cancer clinical trials are expected in 2025, with potential for new registration-enabling studies. Oncolytics Biotech Inc
shares T.ONC are trading up $0.07 at $1.27.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACA&qmodStoryID=7849043356211962
